The role of CXC chemokines and their receptors in the progression and treatment of tumors

Journal of Molecular Histology

Volumn 43, Issue 6, 2012, Pages 699-713

  Zhu, Qingchao ^a   Han, Xiaodong ^a   Peng, Jiayuan ^a   Qin, Huanlong ^a   Wang, Yu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Biological behavior; CXC chemokine; Receptor; Treatment; Tumor

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL14 CHEMOKINE; CXCL15 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL4 CHEMOKINE; CXCL7 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 8; MONOCLONAL ANTIBODY; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL MATURATION; CELL TYPE; COLORECTAL CANCER; DRUG MEGADOSE; DRUG POTENTIATION; ENDOMETRIUM CANCER; ESOPHAGUS CARCINOMA; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NASOPHARYNX CARCINOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SKIN CARCINOMA; TUMOR GROWTH; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; ANIMAL; METABOLISM; NEOPLASM;

ANIMALS; CHEMOKINES, CXC; HUMANS; NEOPLASMS; RECEPTORS, CHEMOKINE;

EID: 84877112601     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-012-9435-x     Document Type: Review

References (114)

1. Addison CL, Daniel TO, Burdick MD et al (2000a) The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. J Immunol 165(9):5269-5277
2. Addison CL, Arenberg DA, Morris SB et al (2000b) The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Genet Ther 11(2):247-261 (Pubitemid 30080383)
3. Addison CL, Belperio JA, Burdick MD et al (2004) Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 4:28 (Pubitemid 40180304)
4. Alvarez H, Opalinska J, Zhou L et al (2011) Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet 7(3):e1001356
5. Angiolillo AL, Sgadari C, Taub DD et al (1995) Human interferon-inducible protein-10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182(1):155-162
6. Arenberg DA, Kunkel SL, Polverini PJ et al (1996a) Interferon-γ- inducible protein IP-10 is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184(3):981-992
7. Arenberg DA, Kunkel SL, Polverini PJ et al (1996b) Inhibition of IL-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97(12):2792-2802 (Pubitemid 26197092)
8. Arenberg DA, Polverini PJ, Kunkel SL et al (1997) The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 62(5):554-562 (Pubitemid 27519764)
9. Arya M, Patel HR, Williamson M (2003) Chemokines: key players in cancer. Curr Med Res Opin 19(6):557-564 (Pubitemid 37122049)
10. Arya M, Ahmed H, Silhi N et al (2007) Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand receptor) interaction in cancer cell migration. Tumor Biol 28(3):123-131 (Pubitemid 46975998)
11. Augsten M, Hägglöf C, Olsson E et al (2009) CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA 106(9):3414-3419
12. Auguste P, Javerzat S, Bikfalvi A (2003) Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 314(1):157-166 (Pubitemid 37409921)
13. Bachelder RE, Wendt MA, Mercurio AM (2002) Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CCR4. Cancer Res 62(24):7203-7206 (Pubitemid 36025239)
14. Baird AM, Gray SG, O'Byrne KJ (2011) Epigenetics underpinning the regulation of the CXC (ELR +) chemokines in non-small cell lung cancer. PLoS One 6(1):e14593
15. Balkwill F (2004a) Cancer and chemokine network. Nat Rev Cancer 4(7):540-550
16. Balkwill F (2004b) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14(3):171-179 (Pubitemid 38586742)
17. Belperio JA, Keane MP, Arenberg DA et al (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68(1):1-8
18. Bertolini F, Dell'Agnola C, Mancuso P et al (2002) CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 62(11):3106-3112 (Pubitemid 34602402)
19. Bikfalvi A (2004) Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 30(3):379-385 (Pubitemid 39037632)
20. Bikfalvi A, Gimenez-Gallego G (2004) The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin Thromb Hemost 30(1):137-144 (Pubitemid 38457308)
21. Bordoni R, Fine R, Murray D et al (1990) Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes. J Cell Biochem 44(4):207-219
22. Brand S, Dambacher J, Beigel F et al (2005) CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion, invasion and MMP-9 activation. Exp Cell Res 310(1):117-130 (Pubitemid 41393693)
23. Brysse A, Mestdagt M, Polette M et al (2012) Regulation of CXCL8/IL-8 expression by zonula occludens-1 in human breast cancer cells. Mol Cancer Res 10(1):121-132
24. Burns JM, Summers BC, Wang Y et al (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203(9):2201-2213 (Pubitemid 44352240)
25. Busuttil A, Weigt SS, Keane MP et al (2009) CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. Eur Respir J 34(3):676-686
26. Couty JP, Gershengorn MC (2004) Insights into the viral G protein-coupled receptor encoded by human herpesvirus type-8. Biol Cell 96(5):349-354 (Pubitemid 38807900)
27. Dias S, Choy M, Rafii S (2001) The role of CXC chemokines in the regulation of tumor angiogenesis. Cancer Invest 19(7):732-738 (Pubitemid 32910992)
28. Ehlert JE, Addison CA, Burdick MD et al (2004) Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 173(10):6234-6240 (Pubitemid 39487781)
29. Ferrer FA, Miller LJ, Andrawis RI et al (1998) Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51(1):161-167 (Pubitemid 28092530)
30. Ferretti E, Di Carlo E, Cocco C et al (2010) Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 133(2):99-105
31. Frederick MJ, Henderson Y, Xu X et al (2000) In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156(6):1937-1950 (Pubitemid 30641763)
32. Giuliani N, Bonomini S, Romagnani P et al (2006) CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 91(11):1489-1497 (Pubitemid 44736115)
33. Guiducci C, Vicari AP, Sanhaletti S et al (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65(8):3437-3446 (Pubitemid 40524630)
34. Gupta SK, Singh JP (1994) Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 127(4):1121-1127 (Pubitemid 24355998)
35. Ha HK, Lee W, Park HJ et al (2011) Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer. Mol Med Report. 4(3):419-424
36. Heidemann J, Ogawa H, Dwinell MB et al (2003) Angiogenic effects of interleukin 8(CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 278(10):8508-8515 (Pubitemid 36800603)
37. Hillinger S, Yang SC, Zhu L et al (2003) EBV-induced molecule1 ligand chemokine (ELC/CCL19) promotes IFN-γ-dependent antitumor responses in a lung cancer model. J Immunol 171(12):6457-6465 (Pubitemid 37532074)
38. Homey B, Muller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Res Immunol. 2(3):175-184 (Pubitemid 37328764)
39. Inoue K, Slaton JW, Eve BY et al (2000) Interleukin-8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6(5):2104-2119 (Pubitemid 30305111)
40. IUIS/WHO (2003) Subcommittee on Chemokine Nomenclature. Chemokine/chemokine receptor nomenclature. Cytokine 21(1):48-49 (Pubitemid 36369377)
41. Kawada K, Sonoshita M, Sakashita H et al (2004) Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 64(11):4010-4017 (Pubitemid 38697317)
42. Keane MP, Belperio JA, Xue YY et al (2004) Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 172(5):2853-2860 (Pubitemid 38263670)
43. Keeley EC, Mehrad B, Strieter RM (2008) Chemokines as mediators of neovascularization. Aeterioscler Thromb Vasc Biol 28(11):1928-1936
44. Keeley EC, Mehrad B, Strieter RM (2010) CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106:91-111
45. Keeley EC, Mehrad B, Strieter RM (2011) Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res 317(5):685-690
46. Kijowski J, Baj-Krzyworzeka M, Majka M et al (2001) The SDF-1 -CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. Stem Cells 19(5):453-466 (Pubitemid 32900088)
47. Kittang AO, Hatfield K, Sand K et al (2010) The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 341:149-172
48. Kulbe H, Levinson NR, Balkwill F et al (2004) The chemokine network in cancer-much more than directing cell movement. Int J Dev Biol 48(5-6):489-496 (Pubitemid 39360399)
49. Lasagni L, Francalanci M, Annunziato F et al (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197(11):1537-1549 (Pubitemid 36682550)
50. Liu Y, Huang H, Saxena A et al (2002) Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther 9(6):533-542 (Pubitemid 34569036)
51. Loetscher M, Loetscher P, Brass N et al (1998) Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 28(11):3696-3705 (Pubitemid 28510780)
52. Luan J, Shattuck BR, Haghnegahdar H et al (1997) Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 62(5):588-597 (Pubitemid 27519769)
53. Luster AD (1998) Chemokines-chemotactic cytokines that mediate inflammation. N Eng J Med 338(7):436-445 (Pubitemid 28135672)
54. Ma X, Norsworthy K, Kundu N et al (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8(3):490-498 (Pubitemid 46988082)
55. Maione TE, Gray GS, Petro J et al (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247(4938):77-79
56. Manna SK, Ramesh GT (2005) Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway. J Biol Chem 280(8):7010-7021 (Pubitemid 40341257)
57. Mc Donnell S, Chaudhry V, Mansilla-soto J et al (1999) Metastatic and non- metastatic colorectal cancer (CRC) cells induce host metalloproteinase production in vivo. Clin Exp Metastasis 17(4):341-349 (Pubitemid 29477580)
58. Mehrad B, Keane MP, Strieter RM (2007) Chemokines as mediators of angiogenesis. Thromb Haemost 97(5):755-762 (Pubitemid 46804315)
59. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33(4):369-385 (Pubitemid 44142736)
60. Moore BB, Arenberg DA, Addison CL et al (1998) CXC chemokines mechanism of action in regulating tumor angiogenesis. Angiogenesis 2(2):123-134 (Pubitemid 128511980)
61. Moore BB, Arenberg DA, Stoy K et al (1999) Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 154(5):1503-1512 (Pubitemid 29226445)
62. Muller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50-56 (Pubitemid 32225831)
63. Muller M, Carter S, Hofer MJ et al (2010) The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10, and CXCL11 in neuroimmunity-a tale of conflict and conundrum. Neuropathol Appl Neurobiol 36(5):368-387
64. Narvaiza I, Mazzolini G, Barajas M et al (2000) Introtumoral coinjection of two adenovirus, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 164(6):3112-3122 (Pubitemid 30148972)
65. Nor JE, Christensen J, Liu J et al (2001) Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 61(5):2183-2188 (Pubitemid 32692045)
66. Norgauer J, Metzner B, Schraufstatter I (1996) Expression and growth-promoting function of IL-8 receptor βin human melanoma cells. J Immunol 156(3):1132-1137 (Pubitemid 26048108)
67. Olbina G, Cieslak D, Ruzdijic S et al (1996) Reversible inhibition of IL-8 receptor βmRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides. Anticancer Res 16(6):3525-3530 (Pubitemid 27085007)
68. Palmer K, Hitt M, Emtage PC et al (2001) Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther 8(4):282-290 (Pubitemid 32237061)
69. Parsonage G, Machado LR, Hui JW et al (2012) CXCR6 and CCR5 localize T lymphocyte subsets in nasopharyngeal carcinoma. Am J Pathol 180(3):1215-1222
70. Pawson T, Scott JD (1997) Signaling through scaffold, anchoring, and adaptor proteins. Science 278(5346):2075-2080 (Pubitemid 28028310)
71. Perollet C, Han ZC, Savona C et al (1998) Platelet factor-4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 91(9):3289-3299 (Pubitemid 28193879)
72. Phillips RJ, Burdick MD, Lutz M et al (2003) The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167(12):1676-1686 (Pubitemid 36760683)
73. Richards BL, Eisma RJ, Spiro JD et al (1997) Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma. Am J Surg 174(5):507-512 (Pubitemid 27486015)
74. Richmond A, Thomas HG (1986) Purification of melanoma growth stimulatory activity. J Cell Physiol 129(3):375-384 (Pubitemid 17190155)
75. Richmond A, Fan GH, Dhawan P et al (2004) How do chemokine/chemokine receptor activations affect tumorigenesis? Novartis Found Symp 256:74-89
76. Rollins Barrett J (2006) Inflammatory chemokines in cancer growth and progression. Euro J Cancer. 42(6):760-767
77. Romagnani P, Annunziato F, Lasagni L et al (2001) Cell cycle-dependent expression of CXC chemokine receptor3 by endothelial cells mediates angiostatic activity. J Clin I nvest. 107(1):53-63 (Pubitemid 32047414)
78. Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18:217-242 (Pubitemid 30365380)
79. Rubin JB, Kung AL, Klein RS et al (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100(23):13513-13518 (Pubitemid 37444773)
80. Ruehlmann JM, Xiang R, Niethammer AG et al (2001) MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res 61(23):8498-8503 (Pubitemid 33131131)
81. Salcedo R, Oppenheim JJ (2003) Role of the chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10(3-4):359-370 (Pubitemid 39004262)
82. Salcedo R, Wasserman K, Young HA et al (1999) Vascular endothelial growth factor and basic fibrolast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovasculaeization induced by stromal-derived factor-l alpha. Am J Pathol 154(4):1125-1135 (Pubitemid 29169747)
83. Salcedo R, Resau JH, Halverson D et al (2000) Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 14(14):2055-2064
84. Sambandam Y, Sundaram K, Liu A et al (2012) CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment. Oncogene. doi: 10.1038/onc.2012.24
85. Schruefer R, Lutze N, Schymeinsky J et al (2005) Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Am J Physiol Heart Circ Physiol 288(3):H1186-H1192 (Pubitemid 40270023)
86. Schwarze SR, Luo J, Isaacs WB et al (2005) Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64(1):67-74 (Pubitemid 40734740)
87. Sgadari C, Farber JM, Angiolillo AL et al (1997) Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89(8):2635-2643 (Pubitemid 27172547)
88. Sharma S, Yang SC, Hillinger S et al (2003) SLC/CCL21-mediated anti-tumor responses require IFN-γ, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2(1):22 (Pubitemid 38751475)
89. Shellenberger TD, Wang M, Gujrati M et al (2004) BRAK/CXCL14 is a potent inhibitor of angiogenesis and is a chemotactic factor for immature dendritic cells. Cancer Res 64(22):8262-8270 (Pubitemid 39496830)
90. Shyamala V, Khoja H (1998) Interleukin-8 receptors R1and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells. Biochemistry 37(45):15918-15924 (Pubitemid 28524763)
91. Singh RK, Gutman M, Radinsky R et al (1994) Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 54(12):3242-3247 (Pubitemid 24208936)
92. Singh S, Wu S, Varney M et al (2011) CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc Res 82(3):318-325
93. Soto H, Wang W, Strieter RM et al (1998) The CC chemokine 6ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci 95(14):8205-8210 (Pubitemid 28326091)
94. Stamatovic SM, Keep RF, Mostarica-Stojkovic M et al (2006) CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J Immunol 177(4):2651-2661 (Pubitemid 44201024)
95. Stewart YJ, Smyth MJ (2009) Chemokine-chemokine receptors in cancer immunotherapy. Immunotherapy 1(1):109-127
96. Strieter RM, Polverini PJ, Kunkel SL et al (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270(45):27348-27357
97. Strieter RM, Belperio JA, Burdick MD et al (2004) CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci 1028:351-360 (Pubitemid 40361836)
98. Strieter RM, Burdick MD, Mestas J et al (2006) Cancer CXC chemokine networks and tumor angiogenesis. Euro J Cancer. 42(6):768-778
99. Struyf S, Burdick MD, Peeters E et al (2007) Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res 67(12):5940-5948 (Pubitemid 46985030)
100. Stuyf S, Burdick MD, Proost P et al (2004) Platelets release CXCL14L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 95(9):855-857 (Pubitemid 39434999)
101. Sugden PH, Clerk A (1997) Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell Signal 9(5):337-351 (Pubitemid 27367575)
102. Takamori H, Oades ZG, Hoch OC et al (2000) Autocrine growth effect of IL-8 and GRO-α on a human pancreatic cancer cell line, Capan-1. Pancreas 21(1):52-56 (Pubitemid 30421934)
103. Tanaka Toshiyuki, Bai Zhongbin, Srinoulprasert Yuttana et al (2005) Chemokines in tumor progression and metastasis. Cancer Sci 96(6):317-322 (Pubitemid 41007465)
104. Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267(2):226-244
105. Vicari Alain P, Caux Christophe (2002) Chemokines in cancer. Cytokine Growth Factor Rev 13(2):143-154 (Pubitemid 34229389)
106. Vicari AP, Treilleux I, Lebecque S (2004) Regulation of the trafficking of tumor-infiltrating dendritic cells by chemokines. Semin Cancer Biol 14(3):161-169 (Pubitemid 38586741)
107. Wang J, Loberg R, Taichman RS (2006) The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 25(4):573-587 (Pubitemid 46071864)
108. Yang J, Richmond A (2004) The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 9(6):846-855 (Pubitemid 38878130)
109. Yoneda J, Kuniyasu H, Crispens MA et al (1998) Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90(6):447-454 (Pubitemid 28160636)
110. Youngs SJ, Ali SA, Taub DD et al (1997) Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71(2):257-266 (Pubitemid 27253000)
111. Zhou Y, Larsen PH, Hao C et al (2002) CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 277(51):49481-49487 (Pubitemid 36014384)
112. Zipin-Roitman A, Meshel T, Sagi-Assif O et al (2007) CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 67(7):3396-3405 (Pubitemid 46724880)
113. Zlotnik A (2004) Chemokines in neoplastic progression. Semin Cancer Biol 14(3):181-185 (Pubitemid 38586743)
114. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12(2):121-127 (Pubitemid 30398626)